Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-17 · accession 0001193125-25-323092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-17 | 2025-12-17 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $38.53 | +2,595 | 663.1K | +0.4% | +$100.0K |
| D | 2025-12-17 | 2025-12-17 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -2,595 | 272.5K | -0.9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-17 | M | A | 2,595 | $38.53 | 663,077 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-12-17 | M | D | 2,595 | $0.00 | 272,505 | D | $38.53 · — to 2032-03-01 | 2,595 Common Stock | (F1) The shares underlying this stock option are fully vested and exercisable. |